This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
HSD17B12 / Very-long-chain 3-oxoacyl-CoA reductase · IHC design guide
Design Immunohistochemistry for HSD17B12
Plan chromogenic HSD17B12 IHC on paraffin sections around the reported cytoplasmic tissue pattern (HPA tissue IHC). Compare high-staining appendix glandular cells with undetected adipocytes (HPA tissue IHC), and optimize the catalog antibody within its 1:10–1:50 IHC-P range (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
HSD17B12 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC); ER membrane (UniProt) | |
| Staining pattern | General cytoplasmic staining across tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep formalin fixation consistent across FFPE sections (standard IHC practice; not target-specific) | |
| Caveat | Staining varies by cell type; adipocytes were not detected (HPA tissue IHC) | |
| Regulation | Expression regulation not established (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage and membrane orientation are unresolved (UniProt) |
Section 1
Recommended HSD17B12 IHC & IF Protocols
The catalog antibody’s IHC-P protocol accompanies published tumor-section protocols (PMC12843542; PMC3607433).
| Sample | FFPE human hepatocarcinoma tissue (datasheet A07397-1) |
| Fixation | Image formalin-fixed; duration unreported (datasheet A07397-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-HSD17B12, 1:10-1:50 (datasheet A07397-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | HSD17B12-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page antigen retrieval); compare the ovarian carcinoma paper’s pH 8.0 retrieval (PMC3607433).
Section 2
What Is the Expected HSD17B12 Staining Pattern?
HSD17B12 is an endoplasmic reticulum membrane protein with three transmembrane segments (UniProt Q53GQ0 topology). In paraffin-section IHC, expect cytoplasmic staining in cell populations with documented expression, including appendix glandular cells and cervix squamous epithelial cells (HPA: general cytoplasmic expression; High in each named cell type). Treat the pattern as a guide: HPA rates tissue IHC Approved, with medium consistency between staining and RNA data (HPA: reliability).
| Cytoplasmic staining in appendix glandular cells or cervix squamous epithelial cells. | This matches documented High staining in those populations (HPA: appendix and cervix tissue IHC). A fine reticular appearance could fit ER localisation, but a chromogenic section need not resolve ER structure (UniProt Q53GQ0: ER membrane; general IHC practice). |
| Predominantly nuclear staining, with little cytoplasmic signal in an expected-positive cell population. | That compartment conflicts with the reported cytoplasmic IHC profile and ER membrane location (HPA: tissue IHC profile; UniProt Q53GQ0 localisation). Suspect nonspecific staining or interpretation artefact; check controls before assigning HSD17B12 positivity (general IHC practice). |
| Strong staining in a cell population listed as Not detected, such as adipocytes or cardiomyocytes. | The result conflicts with those specific HPA observations (HPA: adipocytes and cardiomyocytes Not detected). Consider cross-reactivity or endogenous chromogenic activity, especially if control slides share the signal (general IHC practice); a single discordant slide does not establish either cause. |
| Similar colour over cells, stroma and empty areas, obscuring cell boundaries. | This is diffuse background rather than an interpretable cell-localised pattern (general IHC practice). Assess the no-primary control and detection reagents, then judge signal within identifiable cells against matched background (general IHC practice). |
| No detectable signal in appendix glandular cells despite an intact section. | This misses an HPA High population (HPA: appendix glandular cells). Review the assay and a second documented positive population before concluding biological absence; HPA reports medium staining–RNA consistency, so its profile is a benchmark, not a guarantee for each specimen (HPA: reliability; general IHC practice). |
💡Expected HSD17B12 appearanceCall a result positive when identifiable appendix glandular or cervix squamous epithelial cells show clear cytoplasmic signal above local background, consistent with their HPA High staining; nuclear-only colour or uniform haze is suspect (HPA: tissue IHC profile; UniProt Q53GQ0: ER membrane; general IHC practice).
| Membrane topology and visible compartment (UniProt Q53GQ0 topology). | Three transmembrane segments place HSD17B12 in the ER membrane (UniProt Q53GQ0). Interpret resolved cytoplasmic staining; chromogenic IHC alone cannot prove the stained structure is ER (general IHC practice). |
| Tissue and cell selection (HPA: tissue IHC). | High staining is documented in several distinct populations, including colon endothelial cells and pancreas exocrine glandular cells; adipocytes and myocytes are Not detected (HPA: named tissue entries). Select controls by cell type within the section, rather than by tissue name alone (general IHC practice). |
| Antibody evidence (HPA: HPA016427 IHC Approved). | Approved IHC status supports use of the reported tissue pattern, with medium staining–RNA consistency (HPA: reliability). It does not establish performance for every specimen, retrieval condition or detection system (general IHC practice). |
| IF/ICC question: should the same pattern be expected? | ER membrane localisation suggests a cytoplasmic membrane pattern (UniProt Q53GQ0). HPA lists Membrane for subcellular localisation but provides no ICC/IF images or ICC status for HPA016427; do not treat the IHC pattern as IF validation (HPA: subcellular and antibody records). |
| Processing and isoforms (UniProt Q53GQ0). | UniProt lists two isoforms and a full-length chain of residues 1–312, with no signal peptide, propeptide or annotated glycosylation sites (UniProt Q53GQ0). These entries do not identify the antibody epitope or establish isoform-specific staining. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected-positive appendix glands appear blank. | A failed staining run is possible; HPA reports High staining in appendix glandular cells, but medium staining–RNA consistency limits certainty for an individual specimen (HPA: tissue IHC and reliability). | Check section integrity, detection controls and the IHC-validated antibody's documented retrieval and dilution instructions; repeat with another HPA High cell population as a comparator (general IHC practice; HPA: tissue IHC). |
| Nuclei dominate while cytoplasm remains faint. | This disagrees with HPA's general cytoplasmic profile and UniProt's ER membrane assignment (HPA: tissue IHC profile; UniProt Q53GQ0). The cause cannot be determined from localisation alone. | Compare with a no-primary control and examine counterstain and chromogen separately; score only specific cell-associated signal that survives those checks (general IHC practice). |
| Adipocytes or cardiomyocytes stain strongly. | Both populations are listed as Not detected (HPA: adipocytes and cardiomyocytes). Cross-reactivity or endogenous detection activity are possible explanations (general IHC practice). | Review no-primary and detection-only controls, then compare the suspect cells with an HPA High population processed in the same run (general IHC practice; HPA: tissue IHC). |
| Brown colour spreads through stroma and across many unrelated cell types. | Diffuse deposition or nonspecific binding can obscure the cell-restricted pattern needed for interpretation (general IHC practice). HPA's broad tissue expression does not make uniform background a specific result (HPA: low tissue specificity). | Inspect no-primary control, blocking, washes and chromogen development; reassess localisation only after background permits individual cells to be read (general IHC practice). |
| A breast or prostate glandular-cell section gives weak staining. | HPA records Low staining in those populations, so weak signal can accord with its observations (HPA: breast and prostate glandular cells). | Use an HPA High population to verify the run; interpret the weak section against local background instead of using it alone to judge assay failure (HPA: tissue IHC; general IHC practice). |
| An IF image looks diffuse or does not reproduce the IHC result. | HPA supplies no ICC/IF images and no ICC status for HPA016427, while its tissue observations concern IHC (HPA: subcellular, antibody and tissue records). | Treat IF as a separate assay requiring its own controls and optimisation; use UniProt ER membrane localisation as a localisation hypothesis, not proof that an IF signal is specific (UniProt Q53GQ0; general IF practice). |
Experiment evidence
IHC & IF images showing HSD17B12 staining
A07397-1 · IHCFormalin-fixed and paraffin-embedded human hepatocarcinoma reacted with HSD17B12 Antibody (Center), which was peroxidase-conjugated to the s
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000149084-HSD17B12/tissue/cerebral+cortex#imid_4271732
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000149084-HSD17B12/tissue/colon#imid_4271650
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000149084-HSD17B12/tissue/liver#imid_4271651
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000149084-HSD17B12/tissue/kidney#imid_4271660
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for HSD17B12 IHC & IF
🧪Run appendix first: its glandular cells should stain (HPA: Appendix glandular cells, High). Use skeletal muscle myocytes as the negative tissue (HPA: Skeletal muscle myocytes, Not detected); on the appendix slide, use non-glandular cells as an internal background reference only if they are confirmed to lack staining, since HPA does not designate them as negative.
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for HSD17B12; derive a cell-line control from the positive tissue's cell type (Glandular cells) and confirm it by RNA or western blot first.
Technical controls: Include no-primary (secondary-only) and host- and clonality-matched isotype controls, plus HSD17B12 knockout material or an immunizing-peptide block when available (standard IHC practice). Quench endogenous peroxidase before chromogenic detection and check for endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: The selected antibody has a formalin-fixed, paraffin-embedded tissue example with peroxidase/DAB detection (selected SKU A07397-1 caption), but the supplied evidence reports no target-specific fixation window or retrieval dependency. HSD17B12 is an endoplasmic reticulum membrane protein (UniProt Q53GQ0 topology); whether frozen sections or IF are easier remains unreported in the supplied evidence. No appendix-specific artefact is reported in the supplied evidence.
HPA tissue IHC evidence for HSD17B12
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Colon | Endothelial cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
| Smooth muscle | Smooth muscle cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced HSD17B12 IHC Tips
Troubleshoot HSD17B12 staining in paraffin sections by checking retrieval, cellular distribution, controls, and scoring before interpreting chromogenic signal.
How should I adjust retrieval when HSD17B12 staining is weak in paraffin sections?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page retrieval setting). Let sections cool in buffer for about 20 min, then wash gently and compare the IHC-validated antibody on matched sections processed in the same run (standard IHC practice). If staining remains weak, test a longer exposure to the same citrate buffer first; if morphology permits, compare an EDTA buffer at pH 9 as a fallback while keeping detection conditions constant (standard IHC practice). Judge any gain against tissue preservation and background, using appendix glandular cells as a positive reference (HPA: High in appendix glandular cells).
Could fixation explain weak or uneven HSD17B12 staining?
HSD17B12-specific sensitivity to fixation duration or fixative type is unknown because no comparative fixation evidence is supplied (evidence payload: no comparative fixation data). For paraffin-section IHC, record fixative, time in fixative, section thickness, and storage history for each specimen before comparing staining (standard IHC practice). Keep processing and the pH 6.0, 20 min citrate retrieval consistent across comparison sections so a processing difference does not masquerade as a biological difference (page retrieval setting; standard IHC practice). If an unusually fixed specimen stains poorly, compare it with a routinely processed control in the same run and report the uncertainty rather than assigning a target-specific fixation effect (standard IHC practice).
What cellular pattern should count as plausible HSD17B12 staining?
Expect cytoplasmic staining compatible with an endoplasmic reticulum membrane protein, rather than using nuclear colour as the main positive readout (HPA: general cytoplasmic expression; UniProt Q53GQ0: endoplasmic reticulum membrane). HSD17B12 has 3 predicted transmembrane segments at residues 4–24, 182–202, and 271–291, so a cytoplasmic distribution is more plausible than a sharply nuclear pattern (UniProt Q53GQ0 topology). Compare cell types within intact tissue: appendix glandular cells are reported High, whereas adipocytes are Not detected (HPA: appendix; HPA: adipose tissue). Score staining in identified cells, and check an apparently diffuse signal against the no-primary control before calling it specific (standard IHC practice).
Can this antibody distinguish HSD17B12 isoforms in paraffin sections?
Do not assign staining to one isoform from these sections alone: the record lists 2 isoforms, but supplies no antibody epitope map or isoform-specific IHC validation (UniProt Q53GQ0 isoforms; evidence payload: no epitope map). HSD17B12 has 3 transmembrane segments, so epitope accessibility may depend on which region the antibody recognizes and how retrieval exposes it (UniProt Q53GQ0 topology; standard IHC practice). Check the antibody's mapped immunogen or epitope before interpreting discordant specimens, and use an independent antibody against a distinct region if available (standard IHC practice). Report the result as HSD17B12 immunoreactivity unless isoform specificity has been established independently (standard IHC practice).
How can IF help check the cell type and compartment seen by IHC?
Use IF as a separate validation experiment and pair HSD17B12 with an epithelial marker when checking appendix glandular cells, a reported High cell population (HPA: High in appendix glandular cells; standard IF practice). Choose a red or far-red fluorophore after checking tissue autofluorescence in unstained sections, and acquire single-label controls to assess channel bleed-through (standard IF practice). Because the antibody epitope and its side of the ER membrane are unspecified, compare staining with and without mild detergent permeabilisation before relying on a negative IF result (UniProt Q53GQ0: ER membrane; evidence payload: no epitope map; standard IF practice). Keep the IF interpretation separate from chromogenic IHC scoring (standard IHC/IF practice).
How can I separate HSD17B12 signal from chromogenic background?
Run a no-primary control through the same secondary antibody and DAB steps to locate detection background (standard IHC practice). Quench endogenous peroxidase with 3% hydrogen peroxide for about 10 min, then use an appropriate protein block and wash thoroughly before detection (standard chromogenic IHC practice). If diffuse colour persists, titrate the IHC-validated antibody and shorten DAB development while checking that appendix glandular-cell staining remains detectable (standard IHC practice; HPA: High in appendix glandular cells). Because HSD17B12 has broad reported tissue expression, assess background at the cell level rather than treating every unstained tissue region as a universal negative control (UniProt Q53GQ0: expressed in most tissues tested; standard IHC practice).
How should I score HSD17B12 IHC across specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and cytoplasmic compartment before scoring, consistent with the reported general cytoplasmic pattern (HPA: general cytoplasmic expression; standard IHC practice). For comparable sections, report the percentage of positive target cells and an H-score from 0–300, calculated as the sum of each intensity grade 0–3 multiplied by its percentage of cells (standard IHC practice). Normalise cell counts to the number of evaluable cells, or stained-cell density to sampled tissue area in mm², and exclude folds and necrotic areas consistently (standard IHC practice). Keep retrieval, DAB development, imaging, and scoring thresholds matched across batches; include a reference section to monitor run variation (standard IHC practice).
When should apparent HSD17B12 positivity be treated as artefact?
Treat predominantly nuclear colour as suspect when the expected pattern is cytoplasmic and the protein is assigned to the ER membrane (HPA: general cytoplasmic expression; UniProt Q53GQ0: ER membrane). Recheck cell identity when a claimed positive is confined to adipocytes or cardiomyocytes, which are reported Not detected in tissue IHC (HPA: adipocytes Not detected; HPA: cardiomyocytes Not detected). Edge staining, necrotic deposits, and colour reproduced in a no-primary or peroxidase control warrant exclusion or repeat staining (standard IHC practice). Interpret a reproducible cellular pattern cautiously because HPA rates tissue staining Approved with medium consistency against RNA, and chromogenic intensity alone does not establish enzyme activity (HPA: Approved, medium consistency; standard IHC interpretation).
Boster reagents
Best HSD17B12 / Very-long-chain 3-oxoacyl-CoA reductase IHC Antibodies
A07397-1 has real chromogenic IHC data from formalin-fixed, paraffin-embedded human hepatocarcinoma (IHC image caption); the catalog lists human reactivity (catalog: Human).
Real IHC data
Anti-HSD17B12 Antibody (Center)
Cat # A07397-1
A07397-1 is listed for human IHC-P and has a DAB-stained image of formalin-fixed, paraffin-embedded human hepatocarcinoma (catalog: applications and reactivity; IHC image caption). It is the only SKU provided, and no IF/ICC image is listed (catalog: product list and IF image alts).
Which to pick: For tissue IHC, choose A07397-1: it is a rabbit polyclonal antibody listed for human IHC-P at 1:10–1:50, with an image from formalin-fixed, paraffin-embedded human hepatocarcinoma (catalog: host, polyclonal designation, reactivity, applications and dilution; IHC image caption). No SKU in the payload is listed for IF/ICC (catalog: applications). No cross-species option is listed; A07397-1 lists human reactivity only (catalog: reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q53GQ0 (DHB12_HUMAN, Very-long-chain 3-oxoacyl-CoA reductase).
- Human Protein Atlas. HSD17B12 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. HSD17B12 subcellular location (ICC-IF): Membrane.
- Human Protein Atlas. HSD17B12 antibody validation summary (1 antibodies).
- The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLoS biology 2026 — PMC12843542.
- 17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma. Gynecologic oncology 2012 — PMC3607433.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:16554811 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for HSD17B12 (Very-long-chain 3-oxoacyl-CoA reductase). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC); ER membrane (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A07397-1 at 1:10-1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: FFPE human hepatocarcinoma tissue (datasheet A07397-1); 2. Fixation: Image formalin-fixed; duration unreported (datasheet A07397-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-HSD17B12, 1:10-1:50 (datasheet A07397-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep formalin fixation consistent across FFPE sections (standard IHC practice; not target-specific); Caveat: Staining varies by cell type; adipocytes were not detected (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage and membrane orientation are unresolved (UniProt); Regulation: Expression regulation not established (UniProt). Evidence: UniProt Q53GQ0, HPA tissue IHC · Approved, HPA ICC-IF · Membrane, Datasheet A07397-1, PMC12843542, PMC3607433. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/HSD17B12/immunohistochemistry-ihc-guide.